Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18185637 | 0.97 | MAPK14 (0.51) | MAPK14NAMPTROCK2ROCK1ADRA1A | |
| SCHEMBL16845165 | 0.91 | ADRA1A (0.48) | ROCK2ROCK1ADRA1A | |
| Trifluoroacetic Acid SCHEMBL18185567 | 0.90 | ADRA1A (0.45) | MAPK14NAMPTROCK2ROCK1ADRA1A | |
| SCHEMBL16845091 | 0.80 | ADRA1A (0.62) | ADRA1A | |
| Trifluoroacetic Acid SCHEMBL18185575 | 0.79 | ADRA1A (0.57) | ADRA1A | |
| SCHEMBL16845151 | 0.79 | ADRA1A (0.54) | NAMPTADRA1A | |
| SCHEMBL16845095 | 0.79 | EPHX2 (0.49) | ADRA1ASLC6A4HRH3 | |
| Trifluoroacetic Acid SCHEMBL18185579 | 0.78 | ADRA1A (0.47) | ADRA1A | |
| SCHEMBL16845209 | 0.78 | ADRA1A (0.52) | ADRA1A | |
| Trifluoroacetic Acid SCHEMBL18185594 | 0.76 | EPHX2 (0.49) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| WO-2015091415-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNI3, TNNC1, FABP3 | MAPK14 2153/4885NAMPT 3187/4885ROCK2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.